Amplia Therapeutics Limited
ASX: ATX
Amplia’s losses widen on rising R&D costs, with no revenue and mounting funding challenges as clinical trials progress.
(Source: TradingView) 3-Month Performance Profile of ATX on a DTF compared to S&P/ASX 200 (XJO).
Amplia Therapeutics reported a challenging FY25, with its net loss increasing by 46% year-over-year to $6.57 million, up from $4.50 mil
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
